GeneDx Holdings Corp.
WGSWW
NASDAQ Global Select0.00
USD
+0.00
- -
CIK
0001818331
ISIN
US81663L1199
CUSIP
81663L119
Return %
Stock
S&P500
1Y
-98.60
18.21
3Y
-96.16
64.38
5Y
-99.98
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Katherine A. Stueland
- Full Time Employees
- 1,300
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- North Tower Stamford CT United States of America 06902
- IPO Date
- Jul 23, 2021
- CIK
- 0001818331
- Website
- genedx.com
- Similar Companies
- Business
- GeneDx Holdings Corp. (Nasdaq: WGS, WGSWW) is a genomics company that provides genetic testing services focused on pediatric and rare disease diagnostics; its core offerings include whole exome sequencing tests such as XomeDx, XomeDx Plus, and XomeDxXpress, genome sequencing options like GenomeSeqDx and GenomeXpress, targeted variant testing, chromosomal microarray analysis for genomic abnormalities, and specialized panels for conditions including autism spectrum disorders, cardiomyopathy, inherited eye disorders, skin diseases, muscle conditions, hearing loss, metabolic disorders, neurologic diseases, and mitochondrial disorders. The company also delivers reproductive health screening, women's health diagnostics, somatic oncology testing through its Legacy Sema4 segment, and data and information services leveraging an integrated portfolio of laboratory processes, software tools, and informatics for DNA sample analysis and patient-specific genetic variation reporting. GeneDx operates primarily in the healthcare sector, serving clinicians, healthcare providers, families, health systems, and academic centers with personalized health insights to inform diagnosis, direct treatment, accelerate drug discovery, and enhance health system efficiencies; it maintains an extensive internal database of over 750,000 exomes and genomes sequenced, positioning it as a leader in translating complex genomic data into clinically actionable results. Founded in 2000 and headquartered in Stamford, Connecticut, the company conducts its operations across the United States with global reach through partnerships and AI-enhanced platforms that support decentralized genomic interpretation. In 2025, GeneDx completed its acquisition of Fabric Genomics, Inc. for up to $51 million including milestones, integrating the AI-powered genomic interpretation platform with its rare disease data assets to enable decentralized testing, expedite neonatal intensive care unit workflows, facilitate genomic newborn screening, and expand international market opportunities while enhancing scalability for on-site sequencing and global provider access.
GeneDx Holdings Corp. (NASDAQ:WGSWW) Short Interest Up 262.0% in March
GeneDx Holdings Corp. (NASDAQ:WGSWW) Sees Large Growth in Short Interest